Quest Laboratories
- Market cap
- ₹ 134 Cr.
- P/E
- 9.4x
- P/B
- 1.48x
- 52-week range
- 68.6 – 152.6
- ROE
- 17%
- ROCE
- 18%
- Dividend yield
- 0%
- Debt / equity
- 0.08
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Quest Laboratories Limited is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms, such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. The tablets include Cetirizine Hydrochloride Tablet IP 10 mg, Zinc Sulphate Dispersible Tablet IP, Diclofenac Sodium Tablet BP, and others. It offers dry syrup and suspension, such as Ferrous Sulphate & Folic Acid Syrup, Albendazole Suspension IP, Zinc Oral Solution USP, Alpha Amilase & Pepsine, Sucralfate Suspension, and others. Its ointments include Silver Sulphadiazine Cream IP, Diclofenac Diethylamino IP Gel, and Povidone Iodine Ointment USP.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Quest Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)9.4 against a typical 34.3: cheaper than most peers (1st = cheapest).17th of 220
- Sales growth−30.2% against a typical +15.6% from a year earlier.180th of 197
- Profit growth+47.9% against a typical +18.9% from a year earlier.54th of 160
- Share price, 3 months−10.6% against a typical 0%.148th of 200
- Size₹ 134.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).134th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 24 Jul 2025 | Board Meeting Intimation | QUEST LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 24-Jul-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2025 . |
| 28 May 2025 | Board Meeting Intimation | QUEST LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Other business. |
| 27 Jan 2025 | Other business matters | To consider other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 27 | 15 | 46 | 23 | 26 | 31 | 32 |
| Expenses | 13 | 19 | 14 | 46 | 19 | 22 | 24 | 28 |
| Operating Profit | 2 | 9 | 1 | 1 | 4 | 3 | 7 | 4 |
| OPM % | 11.7% | 32.2% | 4.5% | 1.7% | 16.5% | 13.2% | 22.6% | 12.8% |
| Other Income | 0 | 1 | 0 | 3 | 2 | 1 | 1 | −1 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 1 | 4 | 5 | 4 | 7 | 2 |
| Tax % | 11.5% | 32.4% | 0% | 47.3% | 14.9% | 0% | 40.8% | −16.7% |
| Net Profit | 1 | 6 | 1 | 2 | 4 | 4 | 4 | 3 |
| EPS in Rs | 0.9 | 3.7 | 0.48 | 1.18 | 2.5 | 2.45 | 2.46 | 1.75 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 30%
- 3 Years
- 22%
- TTM
- 8%
- 10 Years
- —
- 5 Years
- 86%
- 3 Years
- 43%
- TTM
- 8%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 26%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Quest Laboratories | ₹ 84.90 | ₹ 134 Cr. | 9.4x | 1.5x | 17% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Anil Kumar Sabarwal
- Executive Chairman of the Board, Managing Director
- Ramkrishna Sharma
- Chief Financial Officer
- Surabhi Gupta
- Compliance Officer, Company Secretary
- Tejaswini Sabarwal
- Whole Time Director
- Vinayak Sabarwal
- Whole Time Director
- Umendra Singh
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.